.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE04_Nelfinavir.Nelfinavir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE04_Nelfinavir.Nelfinavir| name: | Nelfinavir |
| ATC code: | J05AE04 | route: | oral |
| n-compartments | 2 |
Nelfinavir is an orally administered HIV-1 protease inhibitor that was previously used in combination antiretroviral therapy for the treatment of HIV infection. It is less commonly used today due to the availability of newer agents with improved safety and efficacy profiles.
Pharmacokinetic parameters reported for healthy adult volunteers after single oral dose administration in fasting state.
Pfister, M, et al., & Sheiner, LB (2003). Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrobial agents and chemotherapy 47(1) 130–137. DOI:10.1128/AAC.47.1.130-137.2003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12499180
Jackson, KA, et al., & Dudley, MN (2000). A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial. Antimicrobial agents and chemotherapy 44(7) 1832–1837. DOI:10.1128/AAC.44.7.1832-1837.2000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10858338
Hirt, D, et al., & Treluyer, JM (2007). Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples. British journal of clinical pharmacology 64(5) 634–644. DOI:10.1111/j.1365-2125.2007.02885.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/17892516